Is The Ketek Scandal Good For Big Pharma?
This article was originally published in The Pink Sheet Daily
Follow-on biologics legislation could be a tougher sell because of distrust of FDA on the Energy and Commerce Committee.
You may also be interested in...
HONG KONG - Wyeth plans to market a second-generation ketolide in the Asia Pacific region, noting that serious side effects associated with the first generation of the new type of antibiotic have not surfaced
FDA fails to submit subpoenaed documents in House investigation into possible clinical trial fraud.
Study everything together and a scale-up manufacturing after preliminary efficacy results, former FDA commissioners Gottlieb and McClellan and their coauthors recommend in a pair of white papers on how the US should respond to the coronavirus pandemic.